Results 81 to 90 of about 13,529 (168)

Unlocking the Potential of Organoaluminum Reagents for Versatile C─C Couplings Using YPhos‐Pd Catalysts

Advanced Synthesis &Catalysis, Volume 368, Issue 18, 19 September 2026.
A general C─C cross‐coupling method employing earth‐abundant organoaluminium nucleophiles is enabled by electronically highly donating and sterically demanding ylide‐substituted phosphine (YPhos) ligands under Pd catalysis. This protocol represents an organoaluminium cross‐coupling that operates with a single catalyst system across all carbon ...
Nicolas Kaiser, Julius Busse, Ben Wichmann, Viktoria H. Gessner   +3 more
wiley   +1 more source

Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats

Toxicology Reports
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate ...
Sanjib Ghosh, Sweata Sarkar, Maharaj Biswas   +2 more
doaj   +1 more source

Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension

PPAR Research, 2011
Peroxisome proliferator-activated receptor-alpha (PPAR-α) activation by fenofibrate reduces blood pressure and sodium retention during DOCA-salt hypertension. PPAR-α activation reduces the expression of inflammatory cytokines, such as interleukin-6 (IL-
Dexter L. Lee, Justin L. Wilson, Rong Duan, Tamaro Hudson, Ahmed El-Marakby   +4 more
doaj   +1 more source

PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway

Cellular Physiology and Biochemistry, 2017
Background: Impaired wound healing is a common complication of diabetes and is the leading cause of lower extremity amputation. Treatment with fenofibrate, a peroxisome proliferators–activated receptor α (PPARα) agonist, was associated with a lower risk ...
Yaping Deng, Xue Han, Zheng Yao, Yuannan Sun, Jiawen Yu, Jian Cai, Guofei Ren, Guojun Jiang, Feng Han   +8 more
doaj   +1 more source

Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes

Cardiovascular Diabetology
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease.
Jiwon Park, Hangyul Song, Shinje Moon, Yumin Kim, Sungsoo Cho, Kyungdo Han, Cheol-Young Park, Sung Woo Cho, Chang-Myung Oh   +8 more
doaj   +1 more source

Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia

Cost Effectiveness and Resource Allocation
Background This study investigated the cost-effectiveness of using fenofibrate to treat type 2 diabetes in Australia. The financial burden of type 2 diabetes mellitus is estimated to surpass AUD10 billion, mainly due to the cost of diabetic complications
Hansoo Kim, Juntao Lyu, Vikrama Raja, Kyoo Kim   +3 more
doaj   +1 more source

Effectiveness and safety of prolonged fenofibrate therapy after the acute phase of hypertriglyceridemic pancreatitis: A long-term retrospective follow-up study. [PDF]

Medicine (Baltimore)
Zeng L, Liu L, Shen L.
europepmc   +1 more source

Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms. [PDF]

J Pharm Pharm Sci
Ho SC, Lee IXY, Liu C, Yu M, Tan HC, Tan GSW, Liu YC.   +6 more
europepmc   +1 more source

Fenofibrate Protects Against Antipsychotic-Induced Hyperglycemia Through Weight Loss and FGF21 Dependent Mechanisms. [PDF]

FASEB J
Akcan M, Jeromson S, Baranowski BJ, Bellucci A, Trang S, Eisner K, Babicki-Moore A, Alfares H, Arbeau M, Medak K, Hahn M, Wright DC.   +11 more
europepmc   +1 more source

Development and Validation of Isocratic RP-UHPLC Method for Assay of Fenofibrate Tablet. [PDF]

Biomed Chromatogr
Yadav J, Kumar S, Sharma PC, Pandey P, Sharma S, Kaushik D.   +5 more
europepmc   +1 more source